{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:45:32Z","timestamp":1780447532120,"version":"3.54.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,30]]},"DOI":"10.7759\/cureus.47974","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:06:51Z","timestamp":1698678411000},"source":"Crossref","is-referenced-by-count":4,"title":["Catecholaminergic Polymorphic Ventricular Tachycardia and Gene Therapy: A Comprehensive Review of the Literature"],"prefix":"10.7759","author":[{"given":"Elvis","family":"Henriquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin A","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravya R","family":"Mundla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diptish H","family":"Wankhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S","family":"Ketha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaswini","family":"Penke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela C","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza S","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sheheryar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-20-7482","article-title":"Inherited arrhythmia syndromes","volume":"48","author":"Kim JA","year":"2021","unstructured":"Kim JA, Chelu MG. Inherited arrhythmia syndromes. Tex Heart Inst J. 2021, 48:e207482. 10.14503\/THIJ-20-7482","journal-title":"Tex Heart Inst J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2016.01.012","article-title":"Clinical challenges in catecholaminergic polymorphic ventricular tachycardia","volume":"25","author":"Imberti JF","year":"2016","unstructured":"Imberti JF, Underwood K, Mazzanti A, Priori SG. Clinical challenges in catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ. 2016, 25:777-83. 10.1016\/j.hlc.2016.01.012","journal-title":"Heart Lung Circ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia","volume":"119","author":"Hayashi M","year":"2009","unstructured":"Hayashi M, Denjoy I, Extramiana F, et al.. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009, 119:2426-34. 10.1161\/CIRCULATIONAHA.108.829267","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.04.027","article-title":"Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights","volume":"67","author":"Kontula K","year":"2005","unstructured":"Kontula K, Laitinen PJ, Lehtonen A, Toivonen L, Viitasalo M, Swan H. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res. 2005, 67:379-87. 10.1016\/j.cardiores.2005.04.027","journal-title":"Cardiovasc Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2006.08.018","article-title":"Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia","volume":"3","author":"Mohamed U","year":"2006","unstructured":"Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006, 3:1486-9. 10.1016\/j.hrthm.2006.08.018","journal-title":"Heart Rhythm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry","volume":"8","author":"Roston TM","year":"2015","unstructured":"Roston TM, Vinocur JM, Maginot KR, et al.. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015, 8:633-42. 10.1161\/CIRCEP.114.002217","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12512","article-title":"Catecholaminergic polymorphic ventricular tachycardia, an update","volume":"23","author":"P\u00e9rez-Riera AR","year":"2018","unstructured":"P\u00e9rez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MP, Daminello-Raimundo R, de Lucca AA Jr, de Abreu LC. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018, 23:e12512. 10.1111\/anec.12512","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.05.020","article-title":"HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)","volume":"8","author":"Ackerman MJ","year":"2011","unstructured":"Ackerman MJ, Priori SG, Willems S, et al.. HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011, 8:1308-39. 10.1016\/j.hrthm.2011.05.020","journal-title":"Heart Rhythm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2008.10.008","article-title":"Role of ryanodine receptor as a Ca\u00b2(+) regulatory center in normal and failing hearts","volume":"53","author":"Yano M","year":"2009","unstructured":"Yano M, Yamamoto T, Kobayashi S, Matsuzaki M. Role of ryanodine receptor as a Ca\u00b2(+) regulatory center in normal and failing hearts. J Cardiol. 2009, 53:1-7. 10.1016\/j.jjcc.2008.10.008","journal-title":"J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s1050-1738(03)00025-2","article-title":"A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia","volume":"13","author":"Eldar M","year":"2003","unstructured":"Eldar M, Pras E, Lahat H. A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia. Trends Cardiovasc Med. 2003, 13:148-51. 10.1016\/s1050-1738(03)00025-2","journal-title":"Trends Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402546101","article-title":"A cardiac arrhythmia syndrome caused by loss of ankyrin-B function","volume":"101","author":"Mohler PJ","year":"2004","unstructured":"Mohler PJ, Splawski I, Napolitano C, et al.. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A. 2004, 101:9137-42. 10.1073\/pnas.0402546101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00342-7","article-title":"Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome","volume":"105","author":"Plaster NM","year":"2001","unstructured":"Plaster NM, Tawil R, Tristani-Firouzi M, et al.. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001, 105:511-9. 10.1016\/s0092-8674(01)00342-7","journal-title":"Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.08.015","article-title":"Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death","volume":"91","author":"Nyegaard M","year":"2012","unstructured":"Nyegaard M, Overgaard MT, S\u00f8ndergaard MT, et al.. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012, 91:703-12. 10.1016\/j.ajhg.2012.08.015","journal-title":"Am J Hum Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00035","article-title":"Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches","volume":"5","author":"Hohendanner F","year":"2014","unstructured":"Hohendanner F, McCulloch AD, Blatter LA, Michailova AP. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Front Pharmacol. 2014, 5:35. 10.3389\/fphar.2014.00035","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1113\/JP276757","article-title":"Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia","volume":"598","author":"Wleklinski MJ","year":"2020","unstructured":"Wleklinski MJ, Kannankeril PJ, Knollmann BC. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia. J Physiol. 2020, 598:2817-34. 10.1113\/JP276757","journal-title":"J Physiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035428","article-title":"Calcium signaling in cardiomyocyte function","volume":"12","author":"Gilbert G","year":"2020","unstructured":"Gilbert G, Demydenko K, Dries E, Puertas RD, Jin X, Sipido K, Roderick HL. Calcium signaling in cardiomyocyte function. Cold Spring Harb Perspect Biol. 2020, 12:a035428. 10.1101\/cshperspect.a035428","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref17","unstructured":"Cardiovascular Physiology Concepts. Cardiac excitation-contraction coupling. (2023). Accessed. October 26, 2023: https:\/\/cvphysiology.com\/cardiac-function\/cf022."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.24875\/RIC.19002939","article-title":"Basic and clinical insights in catecholaminergic (familial) polymorphic ventricular tachycardia","volume":"71","author":"M\u00e1rquez MF","year":"2019","unstructured":"M\u00e1rquez MF, Totomoch-Serra A, Rueda A, Avelino-Cruz JE, Gallegos-Cortez A. Basic and clinical insights in catecholaminergic (familial) polymorphic ventricular tachycardia. Rev Invest Clin. 2019, 71:226-36. 10.24875\/RIC.19002939","journal-title":"Rev Invest Clin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2022.09","article-title":"Catecholaminergic polymorphic ventricular tachycardia","volume":"11","author":"Abbas M","year":"2022","unstructured":"Abbas M, Miles C, Behr E. Catecholaminergic polymorphic ventricular tachycardia. Arrhythm Electrophysiol Rev. 2022, 11:e20. 10.15420\/aer.2022.09","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2011.10.008","article-title":"Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia","volume":"21","author":"Pflaumer A","year":"2012","unstructured":"Pflaumer A, Davis AM. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ. 2012, 21:96-100. 10.1016\/j.hlc.2011.10.008","journal-title":"Heart Lung Circ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2016.09.012","article-title":"Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?","volume":"14","author":"Ackerman MJ","year":"2017","unstructured":"Ackerman MJ, Priori SG, Dubin AM, et al.. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm. 2017, 14:e41-4. 10.1016\/j.hrthm.2016.09.012","journal-title":"Heart Rhythm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omv057","article-title":"Catecholaminergic polymorphic ventricular tachycardia: a rare cause of recurrent syncope","volume":"2015","author":"Azevedo AI","year":"2015","unstructured":"Azevedo AI, Dias A, Teixeira M, Gama Ribeiro V. Catecholaminergic polymorphic ventricular tachycardia: a rare cause of recurrent syncope. Oxf Med Case Reports. 2015, 2015:337-42. 10.1093\/omcr\/omv057","journal-title":"Oxf Med Case Reports"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2854","article-title":"Flipping syncope: The case of an adolescent athlete with syncopal episodes ultimately diagnosed with catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Kramer CC","year":"2020","unstructured":"Kramer CC, Maldonado JR, Kimball A, Law IH. Flipping syncope: The case of an adolescent athlete with syncopal episodes ultimately diagnosed with catecholaminergic polymorphic ventricular tachycardia. Clin Case Rep. 2020, 8:1409-12. 10.1002\/ccr3.2854","journal-title":"Clin Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.756528","article-title":"Enhanced cytosolic Ca2+ activation underlies a common defect of central domain cardiac ryanodine receptor mutations linked to arrhythmias","volume":"291","author":"Xiao Z","year":"2016","unstructured":"Xiao Z, Guo W, Sun B, et al.. Enhanced cytosolic Ca2+ activation underlies a common defect of central domain cardiac ryanodine receptor mutations linked to arrhythmias. J Biol Chem. 2016, 291:24528-37. 10.1074\/jbc.M116.756528","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-817728-0.00033-4","article-title":"Chapter 33 - Sex differences in catecholaminergic polymorphic ventricular tachycardia","author":"Haugaa K","year":"2020","unstructured":"Haugaa K, Leren I. Chapter 33 - Sex differences in catecholaminergic polymorphic ventricular tachycardia. Sex and Cardiac Electrophysiology. Malik M (ed): Elsevier, Amsterdam; 2020. 389-93. 10.1016\/B978-0-12-817728-0.00033-4"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.01.048","article-title":"Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Sy RW","year":"2011","unstructured":"Sy RW, Gollob MH, Klein GJ, et al.. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011, 8:864-71. 10.1016\/j.hrthm.2011.01.048","journal-title":"Heart Rhythm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2016.09.006","article-title":"A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia","volume":"50","author":"Roston TM","year":"2017","unstructured":"Roston TM, Guo W, Krahn AD, et al.. A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2017, 50:227-33. 10.1016\/j.jelectrocard.2016.09.006","journal-title":"J Electrocardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.073","article-title":"Precision medicine in catecholaminergic polymorphic ventricular tachycardia: JACC Focus Seminar 5\/5","volume":"77","author":"Priori SG","year":"2021","unstructured":"Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Trancuccio A, Kovacic JC. Precision medicine in catecholaminergic polymorphic ventricular tachycardia: JACC Focus Seminar 5\/5. J Am Coll Cardiol. 2021, 77:2592-612. 10.1016\/j.jacc.2020.12.073","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori SG","year":"2015","unstructured":"Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, et al.. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015, 36:2793-867. 10.1093\/eurheartj\/ehv316","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society","volume":"72","author":"Al-Khatib SM","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018, 72:e91-e220. 10.1016\/j.jacc.2017.10.054","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12717","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases","volume":"38","author":"Wilde AA","year":"2022","unstructured":"Wilde AA, Semsarian C, M\u00e1rquez MF, et al.. European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. J Arrhythm. 2022, 38:491-553. 10.1002\/joa3.12717","journal-title":"J Arrhythm"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(99)00461-1","article-title":"Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts","volume":"34","author":"Swan H","year":"1999","unstructured":"Swan H, Piippo K, Viitasalo M, et al.. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol. 1999, 34:2035-42. 10.1016\/s0735-1097(99)00461-1","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000020013.73106.d8","article-title":"Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia","volume":"106","author":"Priori SG","year":"2002","unstructured":"Priori SG, Napolitano C, Memmi M, et al.. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002, 106:69-74. 10.1161\/01.cir.0000020013.73106.d8","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2006.12.048","article-title":"Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Napolitano C","year":"2007","unstructured":"Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007, 4:675-8. 10.1016\/j.hrthm.2006.12.048","journal-title":"Heart Rhythm"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.962027","article-title":"Catecholaminergic polymorphic ventricular tachycardia","volume":"5","author":"Leenhardt A","year":"2012","unstructured":"Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2012, 5:1044-52. 10.1161\/CIRCEP.111.962027","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.086","article-title":"Bidirectional ventricular tachycardia","volume":"54","author":"Richter S","year":"2009","unstructured":"Richter S, Brugada P. Bidirectional ventricular tachycardia. J Am Coll Cardiol. 2009, 54:1189. 10.1016\/j.jacc.2009.03.086","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus031","article-title":"The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands","volume":"14","author":"Hayashi M","year":"2012","unstructured":"Hayashi M, Denjoy I, Hayashi M, et al.. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace. 2012, 14:1344-51. 10.1093\/europace\/eus031","journal-title":"Europace"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.112.970517","article-title":"Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives","volume":"5","author":"van der Werf C","year":"2012","unstructured":"van der Werf C, Nederend I, Hofman N, et al.. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol. 2012, 5:748-56. 10.1161\/CIRCEP.112.970517","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)01946-0","article-title":"Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers","volume":"40","author":"Bauce B","year":"2002","unstructured":"Bauce B, Rampazzo A, Basso C, et al.. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol. 2002, 40:341-9. 10.1016\/s0735-1097(02)01946-0","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2022.06.003","article-title":"Exercise testing using sprint protocol vs Bruce protocol in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Bhardwaj P","year":"2022","unstructured":"Bhardwaj P, Stampe NK, Jespersen CH, Tfelt-Hansen J, Winkel BG. Exercise testing using sprint protocol vs Bruce protocol in catecholaminergic polymorphic ventricular tachycardia. JACC Case Rep. 2022, 4:996-1000. 10.1016\/j.jaccas.2022.06.003","journal-title":"JACC Case Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-020-02199-3","article-title":"The Human Gene Mutation Database (HGMD(\u00ae)): optimizing its use in a clinical diagnostic or research setting","volume":"139","author":"Stenson PD","year":"2020","unstructured":"Stenson PD, Mort M, Ball EV, et al.. The Human Gene Mutation Database (HGMD(\u00ae)): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020, 139:1197-207. 10.1007\/s00439-020-02199-3","journal-title":"Hum Genet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5339","article-title":"Identification of two variants in AGRN and RPL3L genes in a patient with catecholaminergic polymorphic ventricular tachycardia suggesting new candidate disease genes and digenic inheritance","volume":"10","author":"Jaouadi H","year":"2022","unstructured":"Jaouadi H, Chabrak S, Lahbib S, Abdelhak S, Zaffran S. Identification of two variants in AGRN and RPL3L genes in a patient with catecholaminergic polymorphic ventricular tachycardia suggesting new candidate disease genes and digenic inheritance. Clin Case Rep. 2022, 10:e05339. 10.1002\/ccr3.5339","journal-title":"Clin Case Rep"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_908_20","article-title":"Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia","volume":"68","author":"Bansal R","year":"2022","unstructured":"Bansal R, Mahajan A, Vichare S, Lokhandwala Y. Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. J Postgrad Med. 2022, 68:41-3. 10.4103\/jpgm.JPGM_908_20","journal-title":"J Postgrad Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.10.010","article-title":"2020 APHRS\/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families","volume":"18","author":"Stiles MK","year":"2021","unstructured":"Stiles MK, Wilde AA, Abrams DJ, et al.. 2020 APHRS\/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm. 2021, 18:e1-e50. 10.1016\/j.hrthm.2020.10.010","journal-title":"Heart Rhythm"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.965947","article-title":"How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Obeyesekere MN","year":"2011","unstructured":"Obeyesekere MN, Klein GJ, Modi S, et al.. How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011, 4:958-64. 10.1161\/CIRCEP.111.965947","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20140075","article-title":"Short-coupled variant of \"torsades de pointes\" and polymorphic ventricular tachycardia","volume":"102","author":"Chokr MO","year":"2014","unstructured":"Chokr MO, Darrieux FC, Hardy CA, et al.. Short-coupled variant of \"torsades de pointes\" and polymorphic ventricular tachycardia. Arq Bras Cardiol. 2014, 102:e60-4. 10.5935\/abc.20140075","journal-title":"Arq Bras Cardiol"},{"key":"ref47","article-title":"Catecholaminergic polymorphic ventricular tachycardia","author":"Napolitano C","year":"2004","unstructured":"Napolitano C, Mazzanti A, Bloise R, et al.. Catecholaminergic polymorphic ventricular tachycardia. GeneReviews\u00ae. Adam MP, Mirzaa GM, Pagon RA, et al. (ed): University of Washington, Seattle, WA; 2004."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000246","article-title":"Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the Cardiac Channelopathies: a scientific statement from the American Heart Association and American College of Cardiology","volume":"132","author":"Ackerman MJ","year":"2015","unstructured":"Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the Cardiac Channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015, 132:e326-9. 10.1161\/CIR.0000000000000246","journal-title":"Circulation"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.09.010","article-title":"Plakophilin-2 truncation variants in patients clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia and decedents with exercise-associated autopsy negative sudden unexplained death in the young","volume":"5","author":"Tester DJ","year":"2019","unstructured":"Tester DJ, Ackerman JP, Giudicessi JR, Ackerman NC, Cerrone M, Delmar M, Ackerman MJ. Plakophilin-2 truncation variants in patients clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia and decedents with exercise-associated autopsy negative sudden unexplained death in the young. JACC Clin Electrophysiol. 2019, 5:120-7. 10.1016\/j.jacep.2018.09.010","journal-title":"JACC Clin Electrophysiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-17-1032","article-title":"Differential diagnosis between catecholaminergic polymorphic ventricular tachycardia and long QT syndrome type 1-modified Schwartz score","volume":"82","author":"Ozawa J","year":"2018","unstructured":"Ozawa J, Ohno S, Fujii Y, Makiyama T, Suzuki H, Saitoh A, Horie M.  Differential diagnosis between catecholaminergic polymorphic ventricular tachycardia and long QT syndrome type 1-modified Schwartz score. Circ J. 2018, 82:2269-76. 10.1253\/circj.CJ-17-1032","journal-title":"Circ J"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1086\/324565","article-title":"A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel","volume":"69","author":"Lahat H","year":"2001","unstructured":"Lahat H, Pras E, Olender T, et al.. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001, 69:1378-84. 10.1086\/324565","journal-title":"Am J Hum Genet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2006.03.025","article-title":"Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing","volume":"3","author":"Tester DJ","year":"2006","unstructured":"Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC, Ackerman MJ. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm. 2006, 3:800-5. 10.1016\/j.hrthm.2006.03.025","journal-title":"Heart Rhythm"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"13","author":"Leren IS","year":"2016","unstructured":"Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016, 13:433-40. 10.1016\/j.hrthm.2015.09.029","journal-title":"Heart Rhythm"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe H","year":"2009","unstructured":"Watanabe H, Chopra N, Laver D, et al.. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009, 15:380-3. 10.1038\/nm.1942","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity","volume":"109","author":"Liu N","year":"2011","unstructured":"Liu N, Denegri M, Ruan Y, et al.. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res. 2011, 109:291-5. 10.1161\/CIRCRESAHA.111.247338","journal-title":"Circ Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.305347","article-title":"The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2","volume":"116","author":"Bannister ML","year":"2015","unstructured":"Bannister ML, Thomas NL, Sikkel MB, et al.. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. Circ Res. 2015, 116:1324-35. 10.1161\/CIRCRESAHA.116.305347","journal-title":"Circ Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430330406","article-title":"New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action","volume":"33","author":"Kaneko N","year":"1994","unstructured":"Kaneko N. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action. Drug Dev Res. 1994, 33:429-38. 10.1002\/ddr.430330406","journal-title":"Drug Dev Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1126\/science.1094301","article-title":"Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2","volume":"304","author":"Wehrens XH","year":"2004","unstructured":"Wehrens XH, Lehnart SE, Reiken SR, et al.. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004, 304:292-6. 10.1126\/science.1094301","journal-title":"Science"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-10-0680","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S\/+) knock-in mouse model","volume":"74","author":"Kobayashi S","year":"2010","unstructured":"Kobayashi S, Yano M, Uchinoumi H, et al.. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S\/+) knock-in mouse model. Circ J. 2010, 74:2579-84. 10.1253\/circj.cj-10-0680","journal-title":"Circ J"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1816685116","article-title":"Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic","volume":"116","author":"Batiste SM","year":"2019","unstructured":"Batiste SM, Blackwell DJ, Kim K, et al.. Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic. Proc Natl Acad Sci U S A. 2019, 116:4810-5. 10.1073\/pnas.1816685116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125366","article-title":"Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using IPSC models","volume":"10","author":"Penttinen K","year":"2015","unstructured":"Penttinen K, Swan H, Vanninen S, Paavola J, Lahtinen AM, Kontula K, Aalto-Set\u00e4l\u00e4 K. Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using IPSC models. PLoS One. 2015, 10:e0125366. 10.1371\/journal.pone.0125366","journal-title":"PLoS One"},{"key":"ref62","article-title":"Left cardiac sympathetic denervation in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia","volume":"17","author":"Marai I","year":"2015","unstructured":"Marai I, Boulos M, Khoury A. Left cardiac sympathetic denervation in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Isr Med Assoc J. 2015, 17:538-40.","journal-title":"Isr Med Assoc J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.113.000170","article-title":"Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate","volume":"6","author":"Miyake CY","year":"2013","unstructured":"Miyake CY, Webster G, Czosek RJ, Kantoch MJ, Dubin AM, Avasarala K, Atallah J. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol. 2013, 6:579-87. 10.1161\/CIRCEP.113.000170","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.02.049","article-title":"Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia","volume":"110","author":"Marai I","year":"2012","unstructured":"Marai I, Khoury A, Suleiman M, Gepstein L, Blich M, Lorber A, Boulos M. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Am J Cardiol. 2012, 110:72-6. 10.1016\/j.amjcard.2012.02.049","journal-title":"Am J Cardiol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.115.003159","article-title":"Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Waddell-Smith KE","year":"2015","unstructured":"Waddell-Smith KE, Ertresvaag KN, Li J, et al.. Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2015, 8:1151-8. 10.1161\/CIRCEP.115.003159","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz309","article-title":"Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest","volume":"40","author":"van der Werf C","year":"2019","unstructured":"van der Werf C, Lieve KV, Bos JM, et al.. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019, 40:2953-61. 10.1093\/eurheartj\/ehz309","journal-title":"Eur Heart J"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000239465.26132.29","article-title":"Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators","volume":"13","author":"Heidb\u00fcchel H","year":"2006","unstructured":"Heidb\u00fcchel H, Corrado D, Biffi A, et al.. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil. 2006, 13:676-86. 10.1097\/01.hjr.0000239465.26132.29","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrcr.2021.10.004","article-title":"Exercise prescription using an insertable cardiac monitor in a patient with catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Momoi M","year":"2022","unstructured":"Momoi M, Katsumata Y, Kataoka M, Yamagishi H, Fukuda K, Takatsuki S. Exercise prescription using an insertable cardiac monitor in a patient with catecholaminergic polymorphic ventricular tachycardia. HeartRhythm Case Rep. 2022, 8:17-21. 10.1016\/j.hrcr.2021.10.004","journal-title":"HeartRhythm Case Rep"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2018.1557046","article-title":"Insertable cardiac monitors: current indications and devices","volume":"16","author":"Sakhi R","year":"2019","unstructured":"Sakhi R, Theuns DA, Szili-Torok T, Yap SC. Insertable cardiac monitors: current indications and devices. Expert Rev Med Devices. 2019, 16:45-55. 10.1080\/17434440.2018.1557046","journal-title":"Expert Rev Med Devices"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.03.025","article-title":"Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models","volume":"14","author":"Kurtzwald-Josefson E","year":"2017","unstructured":"Kurtzwald-Josefson E, Yadin D, Harun-Khun S, et al.. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models. Heart Rhythm. 2017, 14:1053-60. 10.1016\/j.hrthm.2017.03.025","journal-title":"Heart Rhythm"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010586","article-title":"Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia","volume":"129","author":"Hajjar RJ","year":"2014","unstructured":"Hajjar RJ, Lyon AR. Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia. Circulation. 2014, 129:2633-5. 10.1161\/CIRCULATIONAHA.114.010586","journal-title":"Circulation"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup M","year":"2011","unstructured":"Jessup M, Greenberg B, Mancini D, et al.. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011, 124:304-13. 10.1161\/CIRCULATIONAHA.111.022889","journal-title":"Circulation"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo K","year":"2014","unstructured":"Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014, 114:101-8. 10.1161\/CIRCRESAHA.113.302421","journal-title":"Circ Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa107","article-title":"Gene therapy for inherited arrhythmias","volume":"116","author":"Bezzerides VJ","year":"2020","unstructured":"Bezzerides VJ, Prondzynski M, Carrier L, Pu WT. Gene therapy for inherited arrhythmias. Cardiovasc Res. 2020, 116:1635-50. 10.1093\/cvr\/cvaa107","journal-title":"Cardiovasc Res"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.61","article-title":"Gene therapy to treat cardiac arrhythmias","volume":"12","author":"Bongianino R","year":"2015","unstructured":"Bongianino R, Priori SG. Gene therapy to treat cardiac arrhythmias. Nat Rev Cardiol. 2015, 12:531-46. 10.1038\/nrcardio.2015.61","journal-title":"Nat Rev Cardiol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2010.07.004","article-title":"Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice","volume":"7","author":"Katz G","year":"2010","unstructured":"Katz G, Khoury A, Kurtzwald E, et al.. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. Heart Rhythm. 2010, 7:1676-82. 10.1016\/j.hrthm.2010.07.004","journal-title":"Heart Rhythm"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.304","article-title":"Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia","volume":"7","author":"Lodola F","year":"2016","unstructured":"Lodola F, Morone D, Denegri M, et al.. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2016, 7:e2393. 10.1038\/cddis.2016.304","journal-title":"Cell Death Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/190214-catecholaminergic-polymorphic-ventricular-tachycardia-and-gene-therapy-a-comprehensive-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:21Z","timestamp":1707509361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/190214-catecholaminergic-polymorphic-ventricular-tachycardia-and-gene-therapy-a-comprehensive-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":77,"URL":"https:\/\/doi.org\/10.7759\/cureus.47974","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}